Loading
A phase 1/2 trial of Antibody-Drug Conjugate in advanced solid tumours, run by MBrace Therapeutics, now recruiting.
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT06014658 by MBrace Therapeutics, with 130 participants planned, started 2023-11-07 and due to reach its primary completion in 2026-07. Interventions recorded: Antibody-Drug Conjugate.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MBrace Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/